Press Releases Eyenovia, Inc.

Equities

EYEN

US30234E1047

Market Closed - Nasdaq Other stock markets 04:00:03 2024-05-31 pm EDT			5-day change	1st Jan Change
0.7971 ^USD	+11.95%		+12.06%	-61.68%

May. 15	Transcript : Eyenovia, Inc., Q1 2024 Earnings Call, May 15, 2024
May. 15	Eyenovia, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol	May. 15	AQ
Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th	May. 14	AQ
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension	Apr. 25	AQ
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities	Apr. 08	AQ
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings	Apr. 03	AQ
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	Mar. 18	AQ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	Mar. 15	AQ
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	Mar. 13	AQ
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th	Mar. 11	AQ
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery	Mar. 05	AQ
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	Feb. 13	AQ
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada	Jan. 16	AQ
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update	Nov. 13	AQ
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13	Nov. 06	AQ
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production	Nov. 02	AQ
EYENOVIA TO SPONSOR COURSE ON DRUG DELIVERY INNOVATION AT IJCAHPO'S 51ST ANNUAL CONTINUING EDUCATION PROGRAM	23-10-31	AQ
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program	23-10-30	AQ
EYENOVIA TO PRESENT DATA ON PRESERVATIVE-FREE MICROBIAL INTEGRITY OF THE OPTEJET	23-10-10	AQ
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®	23-10-09	AQ
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference	23-09-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Eyenovia, Inc.

Equities

EYEN

US30234E1047

Press Releases

Filters